BEDFORD, Mass., June 05, 2023 Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and. | June 5, 2023
Peter K. Kaiser, M.D., a world-renowned ophthalmologist and retinal disease expert, to serve as Chief Medical Advisor – RetinaRabia Gurses Ozden, M.D. promoted to Chief Medical OfficerMichael Goldstein, M.D. to transition from Chief Medical Officer and President Ophthalmology to Chief Strategy AdvisorBEDFORD, Mass.-.
12.05.2022 - REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first .